Alimera Sciences Inc Quick Ratio (ALIM) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Alimera Sciences Inc  (NASDAQ: ALIM)

Alimera Sciences Inc's Quick Ratio

ALIM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2024, Quick Ratio deteriorated to 0.68 below Alimera Sciences Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Alimera Sciences Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 2174 to 2305.

Explain Quick Ratio?
How much Cash & cash equivalents ALIM´s has?
What are ALIM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALIM Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change 13.35 % 49.45 % -44.38 % -47.39 % -44.15 %
Y / Y Cash & cash equivalent Change -42.33 % 9.38 % 128.63 % 50.25 % 138.9 %
Quick Ratio MRQ 0.68 0.69 0.55 0.47 1.34
ALIM's Total Ranking # 2305 # 2174 # 1266 # 713 # 995
Seq. Current Liabilities Change -23.44 % -5.13 % 23.66 % 26.2 % 0.95 %
Seq. Cash & cash equivalent Change -24.35 % 18.71 % 45.54 % -55.87 % 43.47 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 411
Healthcare Sector # 760
Overall Market # 2305


Quick Ratio Statistics
High Average Low
6.03 1.94 0.13
(Sep 30 2015)   (Dec 31 2022)




Financial Statements
Alimera Sciences Inc's Current Liabilities $ 16 Millions Visit ALIM's Balance sheet
Alimera Sciences Inc's Cash & cash equivalent $ 11 Millions Visit ALIM's Balance sheet
Source of ALIM's Sales Visit ALIM's Sales by Geography


Cumulative Alimera Sciences Inc's Quick Ratio

ALIM's Quick Ratio for the trailling 12 Months

ALIM Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -24.44 % -33.59 % -41.22 % -3.22 % 54.65 %
Y / Y Cash & cash equivalent TTM Growth 6.65 % 68.38 % 82.58 % 14.04 % -23.62 %
Quick Ratio TTM 0.6 0.72 0.77 0.53 0.42
Total Ranking TTM # 3599 # 2716 # 3064 # 2671 # 3780
Seq. Current Liabilities TTM Growth 2.52 % 10.18 % -20.55 % -15.8 % -9.9 %
Seq. Cash & cash equivalent TTM Growth -14.87 % 2.35 % 14.94 % 6.5 % 34.4 %

Quick ratio ranking by company, industry and sector >> Back to ALIM Financial Strength Comparisons >> Go to Compare ALIM Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q2 2024 to $15.92 millions, cumulative Quick Ratio decreased to 0.6 below the Alimera Sciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 456 other companies have achieved higher Quick Ratio than Alimera Sciences Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 2716 to 3599.

Explain Quick Ratio?
How much Cash & cash equivalents ALIM´s has?
What are ALIM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 457
Healthcare Sector # 961
Within the Market # 3599


trailing twelve months Quick Ratio Statistics
High Average Low
4.3 1.52 0.25
(Sep. 30, 2015)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Rani Therapeutics Holdings Inc   1.86 $ 30.901  Millions$ 16.581  Millions
Purple Biotech Ltd  1.86 $ 7.401  Millions$ 3.987  Millions
Insmed Inc  1.85 $ 1,246.799  Millions$ 673.669  Millions
Cue Biopharma Inc   1.82 $ 30.029  Millions$ 16.459  Millions
Allarity Therapeutics Inc   1.81 $ 19.233  Millions$ 10.616  Millions
Ptc Therapeutics inc   1.79 $ 1,093.293  Millions$ 609.803  Millions
Y mabs Therapeutics inc   1.79 $ 77.806  Millions$ 43.470  Millions
Aldeyra Therapeutics Inc   1.79 $ 49.302  Millions$ 27.595  Millions
Novo Nordisk A  1.77 $ 7,586.826  Millions$ 4,274.367  Millions
Galectin Therapeutics Inc   1.75 $ 25.598  Millions$ 14.617  Millions
Evolus Inc   1.73 $ 93.671  Millions$ 54.118  Millions
Ani Pharmaceuticals Inc  1.72 $ 240.110  Millions$ 139.978  Millions
Cellectar Biosciences Inc   1.71 $ 25.869  Millions$ 15.091  Millions
Alkermes Plc   1.70 $ 876.117  Millions$ 515.549  Millions
Axsome Therapeutics Inc   1.69 $ 315.657  Millions$ 186.570  Millions
Shuttle Pharmaceuticals Holdings Inc   1.69 $ 2.339  Millions$ 1.385  Millions
Equillium Inc   1.68 $ 33.299  Millions$ 19.819  Millions
Tuhura Biosciences Inc   1.66 $ 4.909  Millions$ 2.950  Millions
Vertex Pharmaceuticals Inc  1.63 $ 5,795.500  Millions$ 3,547.200  Millions
G1 Therapeutics Inc   1.62 $ 60.730  Millions$ 37.504  Millions
Zevra Therapeutics Inc   1.62 $ 49.258  Millions$ 30.449  Millions
Gyre Therapeutics Inc   1.61 $ 25.100  Millions$ 15.574  Millions
Verrica Pharmaceuticals Inc   1.59 $ 31.930  Millions$ 20.051  Millions
Acelyrin Inc   1.55 $ 128.211  Millions$ 82.452  Millions
Amicus Therapeutics inc   1.55 $ 260.062  Millions$ 168.066  Millions
Abivax Sa  1.53 $ 161.528  Millions$ 105.279  Millions
Aptevo Therapeutics Inc   1.49 $ 8.066  Millions$ 5.419  Millions
Acadia Pharmaceuticals Inc   1.48 $ 500.942  Millions$ 337.851  Millions
Macrogenics Inc   1.45 $ 83.932  Millions$ 57.906  Millions
Nurix Therapeutics Inc   1.45 $ 116.790  Millions$ 80.779  Millions

Date modified: 2026-09-08T15:11:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.